C16 acid-I-{Lys(C10 diacid)}-KQELRRIGDEF
C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF is a cell-permeable and internalizable PTPN1/2 inhibitor, with IC50 values of 107.6 nM and 3375 nM, respectively. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF restores insulin signaling in HepG2 cells. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF achieves glycemic control in db/db diabetic mice. C16 acid-I-{Lys (C10 diacid)}-KQELRRIGDEF can be used in the research of type 2 diabetes.
For research use only. We do not sell to patients.
- Formula: C94H160N20O24
- Molecular Weight:1954.40
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Fluorescein-labeled Lys9-Flu-D6 (Compound D6) (5 μM; 6-24 h) can penetrate the cell membrane of HepG2 cells, accumulate near the nucleus, and colocalize with ER[1].
Compound D6 (5-20 μM; 24 h) enhances glucose uptake in insulin-resistant HepG2 cells in the 2-NBDG uptake assay[1].
Compound D6 (5-10 μM; 24 h) restores the insulin signaling pathway in HepG2 cells by upregulating the levels of p-IR-β and p-AKT[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HepG2 cells
-
Concentration:5, 10 μM
-
Incubation Time:24 h
-
Result:Significantly increased levels of both p-IR-β and p-AKT compared to the insulin-resistant model group.
-
Cell Line:HepG2 cells
-
Concentration:5 μM
-
Incubation Time:6, 12, 24 h
-
Result:Could penetrate the cell membrane and persist inside the cell for more than 24 hours, accumulating a large amount of intracellular green fluorescence (FAM-labeled peptide) near the cell nucleus.
Parmacokinetics
| Species | Dose | Route | T1/2 | Cmax | Tmax |
|---|---|---|---|---|---|
| Rat[1] | 0.2 mg/kg | s.c. | >200 h | 444.2 ng/mL | 24 h |
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/Ks db/db mice (female, 8-9 weeks old, type 2 diabetes mellitus model)[1]
-
Dosage:0.2 mg/kg; 0.4 mg/kg
-
Administration:s.c.; once weekly; 8 weeks
-
Result:Significantly reduced blood glucose levels, and the hypoglycemic effect is sustained and stable.
Exhibited a long-lasting anti-hyperglycemic effect and duration of action.
Restored circulating glucose levels.
Decreased plasma insulin and C-peptide concentrations to 0.4 mg/kg.
Slightly increased p-Akt and p-STAT3 levels.
Chemical Information
-
Molecular Weight 1954.40
-
Formula C94H160N20O24
-
Sequence
C16 acid-Ile-{Lys(C10 diacid)}-Lys-Gln-Glu-Leu-Arg-Arg-Ile-Gly-Asp-Glu-Phe
-
Sequence Shortening
C16 acid-I-{Lys(C10 diacid)}-KQELRRIGDEF
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Research Protocol for Endocrine Diseases
Endocrine diseases often arise from disrupted hormone production, hormone signaling, or target-tissue responsiveness; for diabetes-focused endocrine disease models, insulin signaling regulates glucose uptake, hepatic glucose output, lipid metabolism, and β-cell compensation. Type 2 diabetes develops through interacting defects in insulin resistance, β-cell dysfunction, adipose inflammation, hepatic glucose overproduction, altered incretin signaling, and ectopic lipid metabolism. A major unresolved question is whether endocrine dysfunction is driven primarily by target-tissue insulin resistance, intrinsic β-cell failure, immune/inflammatory stress, or combined multi-organ failure that differs by disease stage.
-
Research Protocol for Metabolic Diseases
AMP-activated protein kinase, AMPK, is a conserved cellular energy sensor that responds to reduced cellular energy status and coordinates metabolism by increasing ATP-generating catabolic pathways while suppressing ATP-consuming anabolic processes. In metabolic disease research, the AMPK pathway is experimentally relevant because it regulates hepatic lipid synthesis, fatty acid oxidation, glucose production, skeletal-muscle glucose disposal, mTORC1-linked biosynthesis, autophagy, mitochondrial homeostasis, and whole-body energy balance. The central pathway logic is that energy stress, metformin, exercise-like stimulation, or direct AMPK activators increase AMPKα Thr172 phosphorylation and downstream substrate phosphorylation, including ACC and RAPTOR. Phosphorylation of ACC suppresses lipogenesis and supports fatty acid oxidation, whereas phosphorylation of RAPTOR suppresses mTORC1 signaling and links cellular energy status to growth and protein synthesis control. The pathway is linked
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)